This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES. (June 2017)
Record Type:
Journal Article
Title:
ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES. (June 2017)
Main Title:
ME‐401, A NOVEL, ORAL, POTENT AND SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3‐KINASE P110δ (PI3Kδ) IN EARLY CLINICAL DEVELOPMENT FOR B‐CELL LYMPHOID MALIGNANCIES